Based on a recent study from Parker Institute researchers at MD Anderson Cancer Center, we are partnering with Seres Therapeutics to conduct a clinical trial to better understand how the microbiome affects patient responses to immunotherapy with the goal of improving treatments moving forward.
Why It Works:
We will combine the Parker Institute network’s deep knowledge of the microbiome and Seres’ ability to develop the clinical data into a defined therapy for patients. By working closely with Seres and MD Anderson, we can translate research into patient therapies much more rapidly.
This is a first-of-its-kind clinical trial for the Parker Institute. We plan to use this model to partner with other industry organizations to put new, innovative studies from our researchers into the clinic as quickly as possible.